Latest articles
Articles are written for an informed general audience — patients, clinicians, and anyone who wants to navigate the peptide therapy space with accurate information rather than hype.
The post-shortage landscape for GLP-1 medications changed fundamentally in early 2025. This plain-English guide explains the full regulatory timeline, when compounded semaglutide and tirzepatide are still legal in 2026, when they are not, and how to evaluate your options with your clinician.
Read articlePatients exploring peptide therapy face a false binary: unregulated grey-market peptides on one end, thousand-dollar-a-month brand drugs on the other. The middle path — licensed clinician oversight, 503A-compliant compounding, and evidence-based protocols — is what appropriate care actually looks like.
Read articleWe don't have an email newsletter yet — but you can follow new articles through the RSS feed. Add https://yourhealthrx.us/blog/feed.xml to any RSS reader (Feedly, NetNewsWire, Reeder, etc.) to get new posts as they publish. We publish when there's something worth saying — not on an arbitrary schedule.
Ready to go further?
Education is the starting point. If you're considering a peptide protocol, a licensed clinician in our network can evaluate your history and determine what's clinically appropriate for you — anywhere in the US.